KEN SHE (single-dose HPV vaccine)
One shot of HPV vaccine was 97.5% effective against the two most dangerous HPV types, making it realistic to vaccinate the whole world.
Vaccine efficacy 97.5% against persistent HPV16/18 infection at 18 months (NEJM Evidence 2022), sustained at 36 months. Together with the IARC India cohort and Costa Rica trial data, it underpinned the WHO 2022 recommendation for one- or two-dose schedules, adopted by more than 60 countries by 2025 and roughly doubling the number of girls a fixed vaccine supply can protect.
- 97.5 out of 100 people reached this endpoint with Single dose nonavalent HPV.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- This endpoint is not one of the standard survival or response measures; read it alongside the trial's primary result.
- These results apply to the people the trial enrolled: Kenyan women aged 15-20: single dose of bivalent or nonavalent HPV vaccine vs meningococcal control, endpoint persistent HPV16/18 infection. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
2,275 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Vaccine efficacy against persistent HPV16/18 infectionprimary | Single dose nonavalent HPV | — | 97.5% | — | — | link |
Pages like this
not linked directly; found by shared links- PersonJian Zhou
Shares Ian Frazer, Nonavalent HPV vaccine, HPV & HBV vaccination, Prevention we already have is not deployed.
- PersonDouglas R. Lowy
Shares Ian Frazer, Nonavalent HPV vaccine, HPV & HBV vaccination, Cervical cancer.
- PersonDenise A. Galloway
Shares Ian Frazer, HPV & HBV vaccination, Cervical cancer, Head and neck squamous cell carcinoma.
- PersonHarald zur Hausen
Shares Ian Frazer, Nonavalent HPV vaccine, HPV & HBV vaccination, Prevention we already have is not deployed.
- IdeaCommunity-tailored HPV vaccine confidence campaigns with school-based delivery
Shares HPV & HBV vaccination, Prevention we already have is not deployed, Cervical cancer, Head and neck squamous cell carcinoma.
- IdeaEliminate infection-caused cancers: HPV, hepatitis B and C, H. pylori and EBV
Shares HPV & HBV vaccination, Prevention we already have is not deployed, Cervical cancer, Head and neck squamous cell carcinoma.
- IdeaSwitch every country to single-dose HPV vaccination and add catch-up to age 26
Shares HPV & HBV vaccination, Prevention we already have is not deployed, Cervical cancer, Head and neck squamous cell carcinoma.
- Key paperSwedish registry study: HPV vaccination almost eliminates cervical cancer when given before 17
Shares Single-dose HPV vaccination plus HPV self-sampling to reach WHO elimination in low-income countries, HPV & HBV vaccination, Prevention we already have is not deployed, Cervical cancer.